ICTR in the News: Adrian Dobs Featured in MD Magazine
Posted by: Crystal Williams on: September 26, 2016 | Print This Page
This article posted in MD Magazine features Adrian Dobs, MD, MHS, director of the Johns Hopkins Clinical Research Network .
For men who have low or reduced testosterone there can be many reasons for the cause of the condition and can require a variety of treatment methods. A study looked at a new way of delivering testosterone in pill form to help these patients.
Adrian Dobs, MD, MHS, John Hopkins University School of Medicine, said the pill form of delivery was a “new, novel” way to administer testosterone for hypogonadism. The condition of hypogonadism could be from primary testicular failure from trauma or radiation, or resulting from an issue with the pituitary gland, both of which can result in low testosterone levels.
The pill was received orally twice a day, and works by testosterone absorption through the lymphatic system, and therefore does not go directly into the liver. After blood levels were measured, they found the testosterone levels increased without negative impact. The doses were given up to one year.
The present ways to administering testosterone are patch, gel or injection, so having a pill is “a nice option for a male to treat hypogonadism,” Dobs said, since a pill is easy to take. Compared to a patch or gel, which could be transferred to another body by touch, a pill provides a better option, she said.
As the recent trial tested safety, additional studies could test the actual outcomes of increased testosterone levels on the men, Dobs said, such as whether it impacted bone density or muscle mass, for example.
– See more at: http://www.hcplive.com/medical-news/adrian-dobs-from-johns-hopkins-university-school-of-medicine-finding-new-ways-to-treat-hypogonadism#sthash.47vDhHyi.dpuf
Courtesy of Caitlyn Fitzpatrick